Beone Medicines
Clinical trials sponsored by Beone Medicines, explained in plain language.
-
New pill targets common cancer mutation in early trial
Disease control TerminatedThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental lung cancer drug shows promise but trial halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called BG-60366 in 33 people with advanced EGFR-mutant non-small cell lung cancer. The drug is designed to break down the faulty EGFR protein that drives cancer growth. The study aimed to check safety and find the right dose, but…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tested a new oral drug called BG-89894 (SYH2039) in 29 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. The tri…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new experimental drug called BGB-R046, given alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminat…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC